The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Bausch + Lomb has discontinued the development of its BL1107 glaucoma eye drop after a Phase 2 trial failed to meet the primary endpoint of improving visual function. Following the study's results, the company decided to end the program and redirect its focus toward a sustained-release implant for geographic atrophy. Clinical trials for this new redirected program are expected to commence in 2028.